YF Liu
YOU?
Author Swipe
View article: Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed‐loop system (Omnipod® 5) in adults with type 1 diabetes
Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed‐loop system (Omnipod® 5) in adults with type 1 diabetes Open
Aims We aimed to evaluate real‐world glycaemic outcomes of a tubeless hybrid closed‐loop (HCL) insulin delivery system in type 1 diabetes (T1D), exploring the influence of ethnicity and socioeconomic status from a publicly funded system wi…
View article: A study to determine a capillary alternative to the gold standard oral glucose tolerance test - Protocol
A study to determine a capillary alternative to the gold standard oral glucose tolerance test - Protocol Open
Type 1 diabetes (T1D) is a chronic condition caused by the immune destruction of the pancreatic beta cells. T1D has recognised asymptomatic pre-clinical stages, providing an opportunity for early diagnosis, education and treatment which ma…
View article: Surface precipitate analysis of gas atomized Ni-Base superalloy powders
Surface precipitate analysis of gas atomized Ni-Base superalloy powders Open
Powders surface precipitate has strong relations with the microstructure and properties of powder metallurgy components. Morphology, element distribution and crystal structure of the precipitate at gas atomized Ni-base superalloy powders s…
View article: GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T‐CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8)
GOLIDOCITINIB IN TREATING REFRACTORY OR RELAPSED PERIPHERAL T‐CELL LYMPHOMA: PRIMARY ANALYSIS OF THE MULTINATIONAL PIVOTAL STUDY RESULTS (JACKPOT8) Open
Introduction: Currently there is no consensus on the treatment of relapsed/refractory (r/r) PTCL, and patient prognosis was poor. Golidocitinib is an orally available, JAK1-selective inhibitor currently being evaluated in a multinational, …
View article: Evaluating T cell responses prior to the onset of type 1 diabetes
Evaluating T cell responses prior to the onset of type 1 diabetes Open
Aims In the current study we aimed to evaluat T cell phenotypes and metabolic profiles in high‐risk individuals who progressed to type 1 diabetes compared to those remaining disease free. Methods A Fluorspot assay was used to examine T cel…
View article: Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes
Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes Open
Type 1 diabetes is characterized by a loss of tolerance to pancreatic β-cell autoantigens and defects in T regulatory cell (Treg) function. In preclinical models, immunotherapy with MHC-selective, autoantigenic peptides restores immune tol…
View article: Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes
Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes Open
Type 1 diabetes is characterized by a loss of tolerance to pancreatic β-cell autoantigens and defects in T regulatory cell (Treg) function. In preclinical models, immunotherapy with MHC-selective, autoantigenic peptides restores immune tol…
View article: Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes
Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes Open
Type 1 diabetes is characterized by a loss of tolerance to pancreatic β-cell autoantigens and defects in regulatory T-cell (Treg) function. In preclinical models, immunotherapy with MHC-selective, autoantigenic peptides restores immune tol…
View article: Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts Open
OBJECTIVE To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes. RESEARCH DESIGN AND METHODS We ex…
View article: Wnt/β-catenin signaling contributes to vincristine-induced neuropathic pain
Wnt/β-catenin signaling contributes to vincristine-induced neuropathic pain Open
Chemotherapy-induced neuropathic pain (CNP) is the major dose-limiting factor in cancer chemotherapy. However, the mechanisms underlying CNP remain elusive. In the present study, CNP was induced by repeated intraperitoneal injection of vin…
View article: The influence of body mass index and age on C‐peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial‐type 1
The influence of body mass index and age on C‐peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial‐type 1 Open
C-peptide measures are strongly and independently related to BMIZ and age at and soon after the diagnosis of T1D. Adjustments for BMIZ and age cause substantial changes in C-peptide values, and impact the association between glycemia and C…
View article: Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes Open
Immunotherapy using peptide from the self-antigen proinsulin is safe in type 1 diabetes and is associated with changes in immune regulation.
View article: Use of self‐collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study
Use of self‐collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study Open
Aims To evaluate the feasibility of using self‐collected capillary blood samples for islet autoantibody testing to identify risk in relatives of people with Type 1 diabetes. Methods Participants were recruited via the observational TrialNe…
View article: Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?
Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Open
OBJECTIVE We aimed to determine the effect of elevated BMI over time on the progression to type 1 diabetes in youth. RESEARCH DESIGN AND METHODS We studied 1,117 children in the TrialNet Pathway to Prevention cohort (autoantibody-positive …
View article: Stimulated urine C‐peptide creatinine ratio vs serum C‐peptide level for monitoring of β‐cell function in the first year after diagnosis of Type 1 diabetes
Stimulated urine C‐peptide creatinine ratio vs serum C‐peptide level for monitoring of β‐cell function in the first year after diagnosis of Type 1 diabetes Open
Aims To determine if urine C‐peptide/creatinine ratio is a useful tool for monitoring β‐cell function in new‐onset Type 1 diabetes. Methods Data were obtained from a prospective immunomodulation study in people with Type 1 diabetes ≤ 3 mon…